WP1066 / Moleculin, WPD Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
WP1066 / Moleculin
NCT01904123: STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

Checkmark Interim data from trial for glioma and brain metastasis from melanoma
Oct 2020 - Oct 2020: Interim data from trial for glioma and brain metastasis from melanoma
Completed
1
8
US
Laboratory Biomarker Analysis, Pharmacological Study, STAT3 Inhibitor WP1066, WP1066
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm, Recurrent Glioblastoma, Recurrent Malignant Glioma
03/22
03/22
NCT04334863: WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors

Completed
1
10
US
WP1066, STAT3 Inhibitor WP1066
Emory University, CURE Childhood Cancer, Inc., Peach Bowl LegACy Fund
Brain Tumor, Medulloblastoma, Brain Metastases
02/23
02/23

Download Options